Gaubert, Malo Lange, Catharina Garnier-Crussard, Antoine Köbe, Theresa Bougacha, Salma Gonneaud, Julie de Flores, Robin Tomadesso, Clémence Mézenge, Florence Landeau, Brigitte
...
Published in
Alzheimer's Research & Therapy
BackgroundWhite matter hyperintensities (WMH) are frequently found in Alzheimer’s disease (AD). Commonly considered as a marker of cerebrovascular disease, regional WMH may be related to pathological hallmarks of AD, including beta-amyloid (Aβ) plaques and neurodegeneration. The aim of this study was to examine the regional distribution of WMH asso...
Leinenga, Gerhard Koh, Wee Kiat Götz, Jürgen
Published in
Alzheimer's Research & Therapy
BackgroundAducanumab is an anti-amyloid-β (Aβ) antibody that achieved reduced amyloid pathology in Alzheimer’s disease (AD) trials; however, it is controversial whether it also improved cognition, which has been suggested would require a sufficiently high cumulative dose of the antibody in the brain. Therapeutic ultrasound, in contrast, has only be...
Dong, Qiu-Yue Li, Tao-Ran Jiang, Xue-Yan Wang, Xiao-Ni Han, Ying Jiang, Jie-Hui
Published in
Alzheimer's Research & Therapy
IntroductionSubjective cognitive decline (SCD) represents a cognitively normal state but at an increased risk for developing Alzheimer’s disease (AD). Recognizing the glucose metabolic biomarkers of SCD could facilitate the location of areas with metabolic changes at an ultra-early stage. The objective of this study was to explore glucose metabolic...
Schaeverbeke, Jolien M. Gabel, Silvy Meersmans, Karen Luckett, Emma S. De Meyer, Steffi Adamczuk, Katarzyna Nelissen, Natalie Goovaerts, Valerie Radwan, Ahmed Sunaert, Stefan
...
Published in
Alzheimer's Research & Therapy
BackgroundWe examined in cognitively intact older adults the relative weight of cognitive, genetic, structural and amyloid brain imaging variables for predicting cognitive change over a 4-year time course.MethodsOne hundred-eighty community-recruited cognitively intact older adults (mean age 68 years, range 52–80 years, 81 women) belonging to the F...
Martín-Sánchez, Ana Piñero, Janet Nonell, Lara Arnal, Magdalena Ribe, Elena M. Nevado-Holgado, Alejo Lovestone, Simon Sanz, Ferran Furlong, Laura I. Valverde, Olga
...
Published in
Alzheimer's Research & Therapy
BackgroundMajor depression (MD) is the most prevalent psychiatric disease in the population and is considered a prodromal stage of the Alzheimer’s disease (AD). Despite both diseases having a robust genetic component, the common transcriptomic signature remains unknown.MethodsWe investigated the cognitive and emotional behavioural responses in 3- a...
Clark, Christopher Dayon, Loïc Masoodi, Mojgan Bowman, Gene L. Popp, Julius
Published in
Alzheimer's Research & Therapy
BackgroundMultiple pathophysiological processes have been described in Alzheimer’s disease (AD). Their inter-individual variations, complex interrelations, and relevance for clinical manifestation and disease progression remain poorly understood. We hypothesize that specific molecular patterns indicating both known and yet unidentified pathway alte...
Le Guen, Yann Belloy, Michael E. Napolioni, Valerio Eger, Sarah J. Kennedy, Gabriel Tao, Ran He, Zihuai Greicius, Michael D.
Published in
Alzheimer's Research & Therapy
BackgroundMany Alzheimer’s disease (AD) genetic association studies disregard age or incorrectly account for it, hampering variant discovery.MethodsUsing simulated data, we compared the statistical power of several models: logistic regression on AD diagnosis adjusted and not adjusted for age; linear regression on a score integrating case-control st...
Swinnen, Nathalie Vandenbulcke, Mathieu de Bruin, Eling D. Akkerman, Riekje Stubbs, Brendon Firth, Joseph Vancampfort, Davy
Published in
Alzheimer's Research & Therapy
BackgroundIt is currently unknown whether exergaming is efficacious in people with major neurocognitive disorder (MNCD) residing in long-term care facilities. This pilot randomized controlled trial (RCT) explored the efficacy of a stepping exergame program on gait speed, balance, mobility, reaction time, cognitive and neuropsychiatric outcomes, qua...
Tissot, Cécile L. Benedet, Andréa Therriault, Joseph Pascoal, Tharick A. Lussier, Firoza Z. Saha-Chaudhuri, Paramita Chamoun, Mira Savard, Melissa Mathotaarachchi, Sulantha S. Bezgin, Gleb
...
Published in
Alzheimer's Research & Therapy
BackgroundTo investigate the association of plasma pTau181, assessed with a new immunoassay, with neurodegeneration of white matter and gray matter cross-sectionally and longitudinally, in aging and Alzheimer’s disease.MethodsObservational data was obtained from the Alzheimer’s Disease Neuroimaging Initiative, in which participants underwent plasma...
Cicognola, Claudia Janelidze, Shorena Hertze, Joakim Zetterberg, Henrik Blennow, Kaj Mattsson-Carlgren, Niklas Hansson, Oskar
Published in
Alzheimer's Research & Therapy
IntroductionPlasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer’s disease (AD) pathology in the form of AD-related amyloid-β (Aβ) pathology and conversion to AD dementia in a mild cognitive impairment (MCI) cohort.MethodOne hundred sixty MCI ...
